EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Complement Inhibition in Xenotransplantation–Where Should the Complement Cascade be Inhibited?

Akihiro Maenaka iD, Kohei Kinoshita iD, David K C Cooper

Xenotransplantation · 2025

DOI: 10.1111/xen.70087 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Xenotransplantation, 2025. Verfasst von Akihiro Maenaka und 2 weiteren Autor:innen. Beteiligte Einrichtung: Center for Transplantation Sciences, Department of Surgery, Massachusetts General Hospital/Harvard Medical School, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Transplantation, Heterologous, Complement Activation, Complement System Proteins, Complement Inactivating Agents. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 40 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Clinical gene‐edited pig organ xenotransplantation has recently become a reality, but some problems remain. The transgenic expression of human complement‐regulatory proteins in the pig organs is now an accepted means of reducing the impact of complement activation, and immunosuppressive therapy based on CD40/CD154 co‐stimulation pathway blockade has proven a largely effective regimen. However, the potential role of complement inhibitors remains uncertain. The complement cascade is complex and consists of several major pathways (e.g., classical, lectin, alternative, terminal) but with several amplification loops and bypasses. It can be inhibited at several different sites, for example, C1, C3, C5, Factor B, and Factor D. We discuss the effect of the various inhibitors currently available and consider their advantages and disadvantages in relation to xenotransplantation. We tentatively suggest that a C3/C3b complement inhibitor may prove optimal, and that complement inhibition may need to be extended for a prolonged period of time.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Transplantation, HeterologousComplement ActivationComplement System ProteinsComplement Inactivating AgentsHeterograftsAnimalsHumansSwineGraft RejectionAnimals, Genetically Modified

Stichwörter der Autor:innen

complementpigxenotransplantation

Substanzen

Complement System ProteinsComplement Inactivating Agents

Autor:innen und Institutionen

  • Center for Transplantation Sciences, Department of Surgery, Massachusetts General Hospital/Harvard Medical School, Boston, Massachusetts, USA.

ORCID-Profile: Akihiro Maenaka, Kohei Kinoshita

Zitieren

APA

Maenaka, A., Kinoshita, K., & Cooper, D. K. C. (2025). Complement Inhibition in Xenotransplantation–Where Should the Complement Cascade be Inhibited?. Xenotransplantation. https://doi.org/10.1111/xen.70087

Vancouver

Maenaka A, Kinoshita K, Cooper DKC. Complement Inhibition in Xenotransplantation–Where Should the Complement Cascade be Inhibited?. Xenotransplantation. 2025. doi:10.1111/xen.70087

BibTeX
@article{Maenaka2025,
  author = {Maenaka, Akihiro and Kinoshita, Kohei and Cooper, David K C},
  title = {Complement Inhibition in Xenotransplantation–Where Should the Complement Cascade be Inhibited?},
  journal = {Xenotransplantation},
  year = {2025},
  doi = {10.1111/xen.70087}
}
Kostenlos starten →